Safety, Tolerability, And Efficacy Of MFOLFIRINOX ± BNT321 As Adjuvant Therapy Following Curative Resection In Patients With Pancreatic Adenocarcinoma

Study Overview

Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma

This trial is designed as a Phase I/randomized Phase II open-label trial of modified(m) FOLFIRINOX ± BNT321 for adjuvant therapy in pancreatic ductal adenocarcinoma (PDAC) patients post R0 or R1 resection. The Phase I, dose escalation part of this trial will be a limited evaluation of two planned BNT321 dose levels in combination with mFOLFIRINOX chemotherapy (24 weeks) followed by BNT321 monotherapy (24 weeks). Following determination of the combination recommended Phase II dose (RP2D), the Phase II (randomized treatment) part of this trial will be initiated as an open-label 2-arm evaluation of mFOLFIRINOX ± BNT321 (24 weeks) followed by BNT321 monotherapy (24 weeks) in the combination arm only to complete the adjuvant therapy course. Treatment cycles are every 2 weeks (14 days).

The Phase I part of the trial will be a limited dose finding evaluation, whereby a minimal number of BNT321 dose levels will be tested for safety and tolerability in combination with mFOLFIRINOX chemotherapy. Dose escalation will be conducted using a 3+3 design, with up to six additional patients treated at the Phase I defined combination maximum tolerated dose (MTD). Two BNT321 dose levels are initially planned, Dose Level 1 and Dose Level 2. Following evaluation of safety profile for Dose Level 2, additional BNT321 dose levels may be evaluated following safety data review, discussion, and approval by the safety review committee (SRC), and health authority review and approval. Approximately 20 patients will be enrolled into the Phase I part. Following completion of the dose escalation Phase I and identification of the RP2D, the trial will proceed to a randomized Phase II part. For this part, an independent data monitoring committee will be established prior to the inclusion of the first patient in this phase. The Phase II part will be a 2-arm, randomization of mFOLFIRINOX ± BNT321, with up to 300 patients enrolled to enable a robust statistical evaluation of the trial's Phase II primary endpoint, i.e., median disease-free survival (mDFS). Additional evaluations for Phase II will include determination of combination regimen safety and tolerability, determination of overall survival (OS), pharmacokinetic (PK), and pharmacodynamic (PD) analyses including anti-drug antibody (ADA), complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) assessments, cytokine and circulating tumor DNA (ctDNA) assessments.

Pancreatic Cancer

DRUG: BNT321 Dose Level 1
DRUG: BNT321 Dose Level 2
DRUG: mFOLFIRINOX
DRUG: BNT321 RP2D

BNT321-02
2023-506014-47 (EUDRACT_NUMBER Identifier) (EUDRACT_NUMBER: )

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2023-09-11	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2025-01-21
First Submitted that Met QC Criteria 2023-09-29	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2025-01-23
First Posted (ACTUAL) 2023-10-06	Results First Posted N/A	Last Verified 2025-01

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Randomized

Interventional Model:
Sequential

Masking:
Single

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Phase 1 - BNT321 Dose Level 1 + mFOLFIRINOX BNT321 in combination with mFOLFIRINOX chemotherapy (24 weeks) followed by BNT321 monotherapy (24 weeks)	DRUG: BNT321 Dose Level 1 Intravenous infusion DRUG: mFOLFIRINOX Intravenous infusion
EXPERIMENTAL: Phase 1 - BNT321 Dose Level 2 + mFOLFIRINOX BNT321 in combination with mFOLFIRINOX chemotherapy (24 weeks) followed by BNT321 monotherapy (24 weeks)	DRUG: BNT321 Dose Level 2 Intravenous infusion DRUG: mFOLFIRINOX Intravenous infusion
EXPERIMENTAL: Phase 2 - BNT321 RP2D + mFOLFIRINOX BNT321 in combination with mFOLFIRINOX chemotherapy (24 weeks) followed by BNT321 monotherapy (24 weeks)	DRUG: mFOLFIRINOX Intravenous infusion DRUG: BNT321 RP2D Intravenous infusion
ACTIVE_COMPARATOR: Phase 2 - mFOLFIRINOX mFOLFIRINOX chemotherapy (24 weeks) as monotherapy	DRUG: mFOLFIRINOX Intravenous infusion

Primary Outcome Measures	Measure Description	Time Frame
Phase 1 - The proportion (%) of patients with at least one dose of investigational medicinal product (IMP) reporting treatment emergent adverse events (TEAEs)	TEAEs including Grade ≥3, serious, fatal TEAE by relationship.	up to 12 months
Phase 1 - The proportion (%) of patients with at least one dose of IMP reporting occurrence of dose limiting toxicities (DLTs)		up to 42 days after first dose of BNT321
Phase 2 - Disease-free survival (DFS)	DFS is defined as the time from randomization to occurrence of any of the following events, whichever occurs first: * Locoregional recurrence or distant metastases as determined by an independent central radiology assessment. * Occurrence of second primary (same or other) cancer as determined by an independent central radiology assessment. * Death from any cause.	up to 60 months

Secondary Outcome Measures	Measure Description	Time Frame
Phase 1 and 2 - OS	OS is defined as the time from first dose of trial treatment to death from any cause.	up to 60 months
Phase 1 and 2 - Relapsed free survival (RFS)	RFS is defined as the time from randomization to occurrence of any of the following events, whichever occurs first: * Locoregional recurrence or distant metastasis as determined by the investigator. * Death from any cause.	up to 60 months
Phase 1 and 2 - PK assessments: Mean Area under the curve (AUC) values derived from serum concentration of IMP	Mean AUC from patients who are dosed with at least one dose of IMP and who have evaluable PK data in Cycles 2 and 3 followed by sparse sampling through end of trial (EOT).	up to 48 weeks
Phase 1 and 2 - PK assessments: Mean observed maximum concentration (Cmax) derived from serum concentration of IMP	Mean Cmax from patients who are dosed with at least one dose of IMP and who have evaluable PK data in Cycles 2 and 3 followed by sparse sampling through EOT.	up to 48 weeks
Phase 1 and 2 - PK assessments: Median time to reach Cmax (tmax) derived from serum concentration of IMP	Median tmax from patients who are dosed with at least one dose of IMP and who have evaluable PK data in Cycles 2 and 3 followed by sparse sampling through EOT.	up to 48 weeks
Phase 1 and 2 - Percentage of patients with detectable anti-drug antibody (ADA)	Percentage of patients who are dosed with at least one dose of IMP and with detectable ADA formation in Cycles 1 and 3, followed by sparse sampling through EOT	up to 48 weeks
Phase 1 and 2 - Percentage of patients with detectable and durable ADCC and/or CDC activity	Percentage of patients who are dosed with at least one dose of IMP with detectable and durable (measurable throughout time on trial) ADCC and/or CDC activity in Cycles 2 and 4, followed by sparse sampling through EOT	up to 48 weeks
Phase 1 and 2 - Change from baseline for patient-reported health-related quality of life (HRQoL) using the European organisation for research and treatment of cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30)	Change from baseline at end of Cycle 12 for patient-reported HRQoL using EORTC QLQ-C30	up to 60 months
Phase 1 and 2 - Change from baseline for patient-reported HRQoL using EORTC Quality of Life Questionnaire for pancreatic cancer (QLQ-Pan26) questionnaires	Change from baseline at end of Cycle 12 for patient-reported HRQoL using EORTC QLQ-Pan26 questionnaires	up to 60 months
Phase 1 and 2 - Change from baseline in combined item scores from EORTC QLQ-C30	Change from baseline at end of Cycle 12 in combined item scores from EORTC QLQ-C30	up to 60 months
Phase 1 and 2 - Change from baseline in combined item scores from EORTC QLQ-Pan26	Change from baseline at end of Cycle 12 in combined item scores from EORTC QLQ-Pan26.	up to 60 months
Phase 2 - Occurrence of TEAEs including Grade ≥3, serious, fatal TEAE by relationship		up to 12 months
Phase 2 - Occurrence of dose reduction and discontinuation of IMP due to TEAE	Occurrence within a patient.	up to 12 months
Phase 2 - Occurrence of abnormal laboratory parameters	Occurrence within a patient.	up to 48 weeks

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Has signed an informed consent form (ICF) before initiation of any trial-specific procedures
Is >18 years or age deemed to be an adult per local authorities inclusive, at the time of giving written informed consent
Willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions, and other requirements of the trial (per investigator assessment, must be capable of understanding and following trial-related instructions)
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
Has histologically or cytologically confirmed PDAC
Had macroscopically complete resection (R0 or R1 resection, Royal College of Pathologists [RCP] classification) performed between ≥21 and ≤84 days prior to Cycle 1, Day 1 (C1D1). Submission of formalin-fixed paraffin-embedded tissue (FFPE) tumor tissue from resection or biopsy is required
Has no radiologic (computed tomography/magnetic resonance imaging) evidence of metastatic disease, malignant ascites, or pleural effusion through an assessment obtained within 4 weeks of first trial medication (i.e., C1D1)
Full recovery from surgery and able to receive chemotherapy
Has acceptable laboratory parameters.
Is willing to allow collection of pharmacokinetic samples
Agree not to enroll in another trial of an IMP, starting after signing of the ICF and continuously until the last planned visit in this trial
Patients of childbearing potential (POCBP) must not be pregnant. POCBP, male patients who are sexually active with POCBP, and female partners of male patients should use a highly effective method of contraception continuously throughout the trial and for a period of 111 days after the last dose of BNT321 and for 9 months (POCBP) and 6 months (male patients) after the last oxaliplatin dose
POCB who agree not to donate eggs (ova, oocytes) starting after signing of the ICF and continuously throughout the trial and for a period of 3 months after the last dose of BNT321 and for 9 months after the last oxaliplatin dose
Men who are willing to refrain from sperm donation, starting after signing of ICF and continuously throughout the trial until 111 days after receiving the last dose of BNT321 and for 6 months after the last oxaliplatin dose

Patients are pregnant or breastfeeding or planning pregnancy or to father children during the trial or within 60 days after last IMP treatment
A medical, psychological, or social condition which, in the opinion of the investigator, could compromise their wellbeing if they participate in the trial, or that could prevent, limit, or confound the protocol specified assessments or procedures, or that could impact adherence to protocol-described requirements
Had major surgery within 3 weeks of first dose of the trial treatment, where participation in the trial could compromise the patient's wellbeing in the opinion of the investigator
Has abnormal electrocardiograms (ECGs) that are clinically significant, such as Fridericia-corrected QT prolongation >470 msec (for women) and >450 msec (for men), (average of three ECGs at least 5 minutes apart)
Has a history of anaphylactic reaction to human, or humanized, antibody
Have other known active cancer(s) likely to require treatment in the next 2 years
Had prior radiotherapy or systemic treatment for PDAC
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic antiinfective therapy that has been administered less than 2 weeks prior to the first dose of BNT321
Known hypersensitivity to any of the excipients of the experimental product BNT321
Known history of seropositivity for human immunodeficiency virus (HIV) with CD4+ T-cell counts <350 cells/μL and with a history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections
Known history/positive serology for Hepatitis B requiring active antiviral therapy (unless immune due to vaccination or resolved natural infection or unless passive immunization due to immunoglobulin therapy; patients with positive serology must have Hepatitis B virus viral load below the limit of quantification)
Active Hepatitis C virus infection (patients who have completed curative antiviral treatment with Hepatitis C virus viral load below the limit of quantification are allowed)
Use of any IMP or device within 21 days before administration of first dose of trial treatment or ongoing participation in the active treatment phase of another interventional clinical trial
Is subject to exclusion periods from another investigational trial
Are vulnerable individuals as per ICH E6 definition, i.e., individuals whose willingness to participate in a clinical trial may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate.
Serum CA19-9 >180 U/mL within 3 weeks of C1D1
Incomplete macroscopic tumor removal (R2 resection)
Significant cardiovascular risk (past medical history of coronary stenting or myocardial infarction within 6 months, or New York Heart Association (NYHA) Class III/IV, heart failure, or concurrent unstable angina) or risk factors for QT prolongation (sustained Grade 3 or higher hypokalemia, history of unstable arrhythmia or family history of long QT syndrome)
Pre-existing neuropathy
Homozygous UDP glucuronosyltransferase family 1 member A1 (UGT1A1)*28 mutation, if testing required by local regulations
Inflammatory disease of the colon or rectum, or occlusion or sub-occlusion of the intestine or severe post-operative uncontrolled diarrhea
Complete dihydropyrimidine dehydrogenase deficiency, if testing required by local regulations
Received a live vaccine within 3 weeks prior to the first dose of trial treatment
Patients with a contraindication to receiving mFOLFIRINOX
Patients with active or latent tuberculosis or history of Mycobacterium tuberculosis infection currently or within the last 2 years
Individuals committed to an institution by virtue of an order issued either by the judicial or the administrative authorities

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

STUDY_DIRECTOR: BioNTech Responsible Person, BioNTech SE

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record